Results A 53 year-old male presented to the emergency room complaining of diffuse
myalgia, dark urine and loss of appetite. Six days prior, he noted the onset of malaise …

Abstract Colchicine and 3-hydroxy-3-methy-glutaryl coenzyme A (HMG-CoA) reductase
inhibitors are well known to cause myopathy. Myotoxicity is dose-dependent in both drugs; …

The hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely
used hypolipidemic agents which decrease cardiovascular morbidity and mortality in both …

Background: Simvastatin, a 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitor, is
indicated for the treatment of hypercholesterolemia and plays an important role in both the …

Rosuvastatin is a recently approved statin and used widely across the globe for primary and
secondary prevention of atherosclerotic cardiovascular heart disease. It has the highest lipid …

Rhabdomyolysis is a well-documented side effect of statin therapy. This risk is increased
with concurrent use of medications that inhibit cytochrome p450-3A4 (CYP3A4), such as …

We report a patient with renal insufficiency who developed rhabdomyolysis 1 month after
initiating cerivastatin and gemfibrozil for hyperlipidemia. Myopathy caused by HMG-CoA …

Rhabdomyolysis is a life-threatening clinical and biochemical syndrome that results from
injury to skeletal muscle. Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) …

Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin
therapy. Predisposing factors include comorbidities and the concomitant use of cytochrome …

A 62-year-old woman presented to hospital, on general practitioner (GP) advice, with a 15-
day history of slowly progressing muscle weakness. Results showed newly deranged liver …